Study of effectiveness of 3 schedules of administration of erythropoietic colonystimulating factors in anemic patients under chemotherapy for solid or hematology malignancy;Estudio de la efectividad de tres esquemas de administración de factores estimuladores de la eritropoyesis en pacientes con anemia asociada a quimioterapia por una neoplasia sólida o hematologica

Medicina Clinica

Volumn 131, Issue 12, 2008, Pages 447-451

  Pontón Sivillá, José Luis ^a   Feliu Frasnedo, Evaristo ^a   Modamio Charles, Pilar ^b   Mariño Hernández, Eduardo L ^b   Font Pous, Albert ^a   Lezcano Rubio, Clara ^a   Ribera Santasusana, José María ^a   Bonafont Pujol, Xavier ^a  

^a Institut Català d'Oncologia Hospital Germans Trias i Pujol Badalona Barcelona   (Germany)

^b Unidad de Farmacia Clínica   (Spain)

Author keywords

Anemia; Cancer; Darbepoetin alpha; Epoetin alpha; Epoetin beta

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CYTOSTATIC AGENT; GEMCITABINE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; SARCOMA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 63149161752     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13126953     Document Type: Article

References (15)

1. Bokemeyer C., Oechsle K., and Hartmann J.T. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest 35 (2005) 26-31
2. Dranitsaris G., Clemons M., Verma S., Lau C., and Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 6 (2005) 856-863
3. Ben-Hamadi R., Duh M.S., Aggarwal J., Henckler A., McKenzie R.S., and Tak Piech C. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapyinduced anemia. Curr Med Res Opin 21 (2005) 1677-1682
4. Persson U., Borg S., Jansson S., Ekman T., Franksson L., Friesland S., et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in sweden: comparative analysis of drug utilization, costs, and hematologic response. Adv Ther 22 (2005) 208-224
5. García-Altés A., and Puig-Junoy J. Revisión de la evidencia científica sobre la eficiencia del uso de la eritropoyetina. Med Clin (Barc) 127 (2006) 415-421
6. Barrett-Lee P., Bokemeyer C., Gascon P., Nortier J.W., Schneider M., Schrijvers D., et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10 (2005) 743-757
7. Reed S.D., Radeva J.I., Daniel D.B., Fastenau J.M., Williams D., and Schulman K.A. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr Med Res Opin 21 (2005) 1527-1533
8. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
9. Repetto L., Moeremans K., and Annemans L. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev 32 Suppl 2 (2006) 5-9
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 Suppl 1 (2002) 1-266
11. Oton C., Penate G., and Oton L.F. Eritropoyetina en la anemia del paciente oncológico. Luces y sombras. Med Clin (Barc) 125 (2005) 796
12. Mark T.L., McKenzie R.S., Fastenau J., and Piech C.T. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 21 (2005) 1347-1354
13. Waltzman R., Croot C., Justice G.R., Fesen M.R., Charu V., and Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10 (2005) 642-650
14. Pujade-Lauraine E., Richard A.J., Sapede C., and Hayward C. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice. Oncol Rep 14 (2005) 1037-1044
15. Herrington J.D., Davidson S.L., Tomita D.K., Green L., Smith R.E., and Boccia R.V. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 62 (2005) 54-62